Novo Nordisk Cuts Prices For Ozempic And Wegovy Starting Dose In India

Novo Nordisk has announced a price reduction for its popular medications Ozempic and Wegovy in India. The starting dose of 0.25 mg will now cost 1,415 rupees per week, making these treatments more accessible to patients managing diabetes and obesity.

Price Revision And Accessibility
The revised pricing reflects Novo Nordisk’s commitment to expanding access to innovative therapies in India. By lowering the entry cost, the company is addressing affordability concerns while supporting patients in initiating treatment with clinically proven solutions.

Impact On Healthcare Market
India faces rising cases of diabetes and obesity, creating urgent demand for effective therapies. The reduced pricing of Ozempic and Wegovy is expected to encourage wider adoption, strengthen patient adherence, and position Novo Nordisk as a key player in the country’s metabolic health segment.

Key Highlights

• Starting dose of 0.25 mg priced at 1,415 rupees per week
• Applies to both Ozempic and Wegovy in India
• Supports affordability and patient access
• Targets growing diabetes and obesity treatment demand

Sources: Company announcement, healthcare market updates